Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Anxu Biotech, indicating a decline in revenue and profit while comparing its valuation metrics to industry averages [1][2] - Anxu Biotech's closing stock price is 39.22 yuan, with a rolling PE ratio of 31.92, marking a new low in 22 days, and a total market capitalization of 4.984 billion yuan [1] - The company ranks 70th in the medical device industry, which has an average PE ratio of 51.58 and a median of 37.46 [1][2] Group 2 - As of the first quarter of 2025, six institutions hold shares in Anxu Biotech, with a total of 50.3836 million shares valued at 1.998 billion yuan [1] - Anxu Biotech specializes in the research, production, and sales of POCT reagents and instruments, having received multiple certifications including EU CE, Canadian, and Australian certifications [1] - The latest financial report for the first quarter of 2025 shows a revenue of 115 million yuan, a year-on-year decrease of 10.90%, and a net profit of 34.0296 million yuan, down 51.52% year-on-year, with a gross margin of 42.32% [1]

最新一期业绩显示，2025年一季报，公司实现营业收入1.15亿元，同比-10.90%；净利润3402.96万元， 同比-51.52%，销售毛利率42.32%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安旭生物30.7724.990.9248.05亿行业平均 49.1247.184.49104.96亿行业中值36.0737.112.4149.03亿1英科医疗9.6910.450.86153.16亿2九安医疗 10.1410.250.80171.07亿3新华医疗14.2913.251.1791.61亿4奥美医疗15.1114.811.5554.59亿5康德莱 15.2015.211.2632.76亿6振德医疗15.4114.520.9855.93亿7山东药玻15.5915.641.79147.46亿8维力医疗 16.0516.691.8836.61亿9奥泰生物16.1917.071.3151.64亿10九强生物16.3315.192.0080.89亿11安杰思 17.2317.442.0851.16亿12三鑫医疗18.3518.353.0241.74亿 来源：金融界 6月24日，安旭生物今日收盘 ...

6月18日，安旭生物今日收盘37.48元，下跌1.13%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到30.51倍，总市值47.63亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均49.10倍，行业中值36.43倍，安旭生物排 名第69位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13安旭生物30.5124.770.9147.63亿行业平均 49.1047.114.54105.10亿行业中值36.4336.872.3948.92亿1英科医疗9.5610.310.85151.03亿2九安医疗 10.1210.230.80170.79亿3新华医疗14.2213.181.1691.18亿4振德医疗14.6413.800.9353.16亿5康德莱 14.7414.751.2231.75亿6奥美医疗14.8614.571.5353.70亿7山东药玻15.7315.781.81148.78亿8九强生物 15.7414.641.9377.95亿9维力医疗15.7716.391.8535.96亿10奥泰生物16.0716.951.3051.26亿11安杰思 17.3817.582. ...

Company Overview - Anxu Bio focuses on the research, production, and sales of POCT (Point-of-Care Testing) reagents and instruments, with a product range covering eight major areas including drug detection, infectious disease detection, chronic disease detection, pregnancy detection, tumor detection, myocardial detection, biochemical detection, and allergen detection [1] - The company has developed a proprietary technology platform for antigen-antibody production and has established mature immunochromatography and dry biochemical diagnostic technology platforms [1] - Anxu Bio's products are exported to over 150 countries, including the USA, Germany, the UK, Canada, Russia, Mexico, Thailand, Indonesia, and Poland, positioning it as one of the few Chinese suppliers capable of competing with multinational in vitro diagnostic giants in the international POCT market [1] Financial Performance - For Q1 2025, Anxu Bio reported a revenue of 115 million yuan, representing a year-on-year decrease of 10.90%, and a net profit of 34.03 million yuan, down 51.52% year-on-year [2] - The company's gross profit margin stands at 42.32% [2] Market Position - As of May 9, Anxu Bio's stock closed at 36.34 yuan, with a rolling price-to-earnings (PE) ratio of 29.58 times, and a total market capitalization of 4.618 billion yuan [1] - The average PE ratio for the medical device industry is 48.98 times, with a median of 36.16 times, placing Anxu Bio at the 67th position in the industry ranking [1][2] - As of Q1 2025, six institutions hold shares in Anxu Bio, including four funds, with a total holding of 50.38 million shares valued at 1.998 billion yuan [1]